Responding to changes in the unregulated drug supply: the need for a dynamic approach to drug checking technologies.
Responding to changes in the unregulated drug supply: the need for a dynamic approach to drug checking technologies.
复制标题
应对不受监管的药品供应的变化：需要采用动态方法进行药品检查技术。
DOI：
10.1080/00952990.2023.2226312
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Ti,Lianping
中科院分区：
文献类型：
--
作者：
Bhuiyan,Ishmam;Tobias,Samuel;Ti,Lianping
药物检查服务为使用药物的个人提供测试其药物样品是否存在高效力物质的能力。然而，最近有人担心现有的即时药物检查技术，如免疫测定条和傅里叶变换红外光谱法（FTIR），是否足以识别不受管制的药物供应中的物质。在北美不受管制的供应中发现了卡芬太尼和硝氮类阿片，这些物质甚至比芬太尼更有效，对我们现有的药物检查策略构成了挑战。例如，依替唑仑最近已渗透到北美不受管制的药物供应中，并已证明有能力逃避护理点药物检查技术。为了应对不断变化的性质的不受管制的供应，我们认为，药物检查技术和服务提供模式必须不断适应不断变化的药物市场。我们提供了两个新兴技术的例子，纸喷雾质谱和表面增强拉曼光谱，解决了现有技术的许多缺点。对于这两种技术，我们讨论了它们的可行性，它们可以在哪里提供，它们的优势，以及它们如何解决我们现有技术中的差距。我们认为，这些技术和其他新兴技术可以整合到未来的药物检查方法中，灵活使用不同的技术和服务提供方法，以适应药物供应的变化。
Drug checking services provide individuals who use drugs with the ability to test samples of their drugs for the presence of highly potent substances. However, there has been recent concern about whether the existing repertoire of point-of-care drug checking technologies, such as immunoassay strips and Fourier-transform infrared spectroscopy (FTIR), are adequate in identifying substances in the unregulated drug supply. Carfentanil and nitazene opioids, substances that are even more potent than fentanylin vitro, have been found in the unregulated supply in North America and pose a challenge to our existing drug checking strategy. For example, etizolam has recently permeated the unregulated drug supply in North America, and has demonstrated the ability to evade point-of-care drug checking technologies. In response to the incessantly changing nature of the unregulated supply, we argue that drug checking technologies and service delivery models must continuously adapt alongside constantly changing drug markets. We provide two examples of emerging technologies, paper spray-mass spectrometry and surface-enhanced Raman spectroscopy, which address many of the shortcomings of existing technologies. For both technologies, we discuss their feasibility, where they can be offered, their advantages, and how they address gaps in our existing technologies. We contend that these technologies, and other emerging technologies, can be integrated into a future approach to drug checking that flexibly uses different technologies and service delivery methods to adapt to changes in the drug supply.